TABLE I.
Outcomes in 109 breast cancer patients undergoing controlled ovarian stimulation for fertility preservation
| Variable | Patient group | p Value | |||
|---|---|---|---|---|---|
| Overall | IFP | LFP | LP | ||
| Patients (n) | 109 | 41 | 21 | 47 | |
| Mean aspirated oocytes (n) | 11.62±7.96 | 10.95±7.23 | 10.38±8.0 | 12.77±8.54 | NS |
| Mean vitrified oocytes (n) | 9.60±6.87 | 8.927±6.75 | 7.952±5.38 | 10.94±7.43 | NS |
| Age (years) | 31.27 ± 4.23 | 31.37±3.48 | 29.76±4.94 | 31.85±4.41 | NS |
| Mean FSH or hMG dose (IU) | 2610±716.51 | 2577±670.19 | 2387±615.31 | 2738±780.9 | 0.04457a |
| Mean days of stimulation (n) | 10±1.39 | 9.854±1.33 | 9.714±1.31 | 10.26±1.45 | NS |
| Mean serum estradiol (pg/mL) | 706.3±450.48 | 761±439.93 | 677.8±503.39 | 671.2±440.1 | NS |
a
Statistically significant difference between the LFP and LP groups.
IFP = initial follicular phase; LFP = late follicular phase; LP = luteal phase; NS = statistically nonsignificant; FSH = follicle-stimulating hormone; hMG = human menopausal gonadotropin.